With Honor-B (02256): The first patient in the clinical trial of FGFR2/3 inhibitor ABSK061 for the treatment of cartilage dysplasia has completed dosing.

Wisdom Finance APP News, Healthee-B (02256) announced that on December 16, 2025, Healthee Biomedical Technology Co., Ltd. ("Healthee Medicine") announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed dosing for the first patient in a Phase II clinical trial for children aged 3-12 with Achondroplasia ("ACH").